Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.

Gorbounov M, Carleton NM, Asch-Kendrick RJ, Xian L, Rooper L, Chia L, Cimino-Mathews A, Cope L, Meeker A, Stearns V, Veltri RW, Bae YK, Resar LMS.

Breast Cancer Res Treat. 2019 Sep 17. doi: 10.1007/s10549-019-05419-1. [Epub ahead of print]

PMID:
31531802
2.

Equity and diversity in academic medicine: a perspective from the JCI editors.

Resar LM, Jaffee EM, Armanios M, Jackson S, Azad NS, Horton MR, Kaplan MJ, Laiho M, Maus MV, Sumner CJ, Wheelan SJ, Wills-Karp M.

J Clin Invest. 2019 Oct 1;129(10):3974-3977. doi: 10.1172/JCI130902. No abstract available.

3.

Approaches to Bloodless Surgery for Oncology Patients.

Frank SM, Chaturvedi S, Goel R, Resar LMS.

Hematol Oncol Clin North Am. 2019 Oct;33(5):857-871. doi: 10.1016/j.hoc.2019.05.009. Epub 2019 Jul 31. Review.

PMID:
31466609
4.

Genetic Engineering of Primary Mouse Intestinal Organoids Using Magnetic Nanoparticle Transduction Viral Vectors for Frozen Sectioning.

Xian L, Chia L, Georgess D, Luo L, Shuai S, Ewald AJ, Resar LMS.

J Vis Exp. 2019 May 10;(147). doi: 10.3791/57040.

PMID:
31132065
5.

Greater anemia tolerance among hospitalized females compared to males.

Visagie M, Pearson KR, Purvis TE, Gehrie EA, Resar LMS, Frank SM.

Transfusion. 2019 Aug;59(8):2551-2558. doi: 10.1111/trf.15338. Epub 2019 May 7.

PMID:
31063596
6.

Preoperative treatment of anemia and outcomes in surgical Jehovah's Witness patients.

Chaturvedi S, Koo M, Dackiw L, Koo G, Frank SM, Resar LMS.

Am J Hematol. 2019 Feb;94(2):E55-E58. doi: 10.1002/ajh.25359. Epub 2018 Dec 18. No abstract available.

PMID:
30474135
7.

PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.

Carleton NM, Zhu G, Gorbounov M, Miller MC, Pienta KJ, Resar LMS, Veltri RW.

Prostate. 2018 May;78(7):547-559. doi: 10.1002/pros.23499. Epub 2018 Mar 9.

8.

HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche.

Xian L, Georgess D, Huso T, Cope L, Belton A, Chang YT, Kuang W, Gu Q, Zhang X, Senger S, Fasano A, Huso DL, Ewald AJ, Resar LMS.

Nat Commun. 2017 Apr 28;8:15008. doi: 10.1038/ncomms15008.

9.

Hmga1 deficiency: "SAC-King" the SAC genes to incite chromosomal instability.

Xian L, Reddy KA, Resar LM.

Cell Cycle. 2017 Jan 2;16(1):17-18. doi: 10.1080/15384101.2016.1214034. Epub 2016 Dec 15. No abstract available.

10.

Bloodless medicine: current strategies and emerging treatment paradigms.

Resar LM, Wick EC, Almasri TN, Dackiw EA, Ness PM, Frank SM.

Transfusion. 2016 Oct;56(10):2637-2647. doi: 10.1111/trf.13736. Epub 2016 Jul 29. Review.

PMID:
27473810
11.

Patent foramen ovale in adults with sickle cell disease and stroke.

Razdan S, Strouse JJ, Reddy A, Resar DF, Hasan RK, Resar JR, Naik RP, Urrutia VC, Lanzkron S, Resar LM.

Am J Hematol. 2016 Sep;91(9):E358-60. doi: 10.1002/ajh.24440. Epub 2016 Jul 20. No abstract available.

12.

The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.

Hillion J, Roy S, Heydarian M, Cope L, Xian L, Koo M, Luo LZ, Kellyn K, Ronnett BM, Huso T, Armstrong D, Reddy K, Huso DL, Resar LMS.

Gynecol Oncol. 2016 Jun;141(3):580-587. doi: 10.1016/j.ygyno.2016.03.020. Epub 2016 Apr 8.

13.

The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Sumter TF, Xian L, Huso T, Koo M, Chang YT, Almasri TN, Chia L, Inglis C, Reid D, Resar LM.

Curr Mol Med. 2016;16(4):353-93. Review.

14.

Ultramassive transfusion: give blood, save a life.

Frank SM, Johnson DJ, Resar LM.

Transfusion. 2016 Mar;56(3):546-8. doi: 10.1111/trf.13403. No abstract available.

PMID:
26954450
15.

STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.

Belton A, Xian L, Huso T, Koo M, Luo LZ, Turkson J, Page BD, Gunning PT, Liu G, Huso DL, Resar LM.

Leuk Lymphoma. 2016 Nov;57(11):2681-4. doi: 10.3109/10428194.2016.1153089. Epub 2016 Mar 8. No abstract available.

16.

The Efficacy and Utility of Acute Normovolemic Hemodilution.

Grant MC, Resar LM, Frank SM.

Anesth Analg. 2015 Dec;121(6):1412-4. doi: 10.1213/ANE.0000000000000935. No abstract available.

PMID:
26579641
17.

Hemoglobin thresholds for transfusion in pediatric patients at a large academic health center.

Klaus SA, Frank SM, Salazar JH, Cooper S, Beard L, Abdullah F, Fackler JC, Heitmiller ES, Ness PM, Resar LM.

Transfusion. 2015 Dec;55(12):2890-7. doi: 10.1111/trf.13296. Epub 2015 Sep 29.

PMID:
26415860
18.

Through a Gender Lens: A View of Gender and Leadership Positions in a Department of Medicine.

Monroe AK, Levine RB, Clark JM, Bickel J, MacDonald SM, Resar LM.

J Womens Health (Larchmt). 2015 Oct;24(10):837-42. doi: 10.1089/jwh.2014.5054. Epub 2015 Jul 22.

PMID:
26200812
19.

Characterizing metabolic changes in human colorectal cancer.

Williams MD, Zhang X, Park JJ, Siems WF, Gang DR, Resar LM, Reeves R, Hill HH Jr.

Anal Bioanal Chem. 2015 Jun;407(16):4581-95. doi: 10.1007/s00216-015-8662-x. Epub 2015 May 6.

PMID:
25943258
20.

How I treat priapism.

Anele UA, Le BV, Resar LM, Burnett AL.

Blood. 2015 Jun 4;125(23):3551-8. doi: 10.1182/blood-2014-09-551887. Epub 2015 Mar 25.

21.

IBRUTinib: BRUTe force against bortezomib-resistant myeloma cells.

Xian L, Huff CA, Resar LM.

Cell Cycle. 2015;14(9):1349-50. doi: 10.1080/15384101.2015.1022058. No abstract available.

22.

Bloodless medicine: what to do when you can't transfuse.

Resar LM, Frank SM.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):553-8. doi: 10.1182/asheducation-2014.1.553. Epub 2014 Nov 18. Review.

PMID:
25696910
23.

Efficacy of education followed by computerized provider order entry with clinician decision support to reduce red blood cell utilization.

Zuckerberg GS, Scott AV, Wasey JO, Wick EC, Pawlik TM, Ness PM, Patel ND, Resar LM, Frank SM.

Transfusion. 2015 Jul;55(7):1628-36. doi: 10.1111/trf.13003. Epub 2015 Feb 3.

PMID:
25646579
24.

HMGA1 drives metabolic reprogramming of intestinal epithelium during hyperproliferation, polyposis, and colorectal carcinogenesis.

Williams MD, Zhang X, Belton AS, Xian L, Huso T, Park JJ, Siems WF, Gang DR, Resar LM, Reeves R, Hill HH Jr.

J Proteome Res. 2015 Mar 6;14(3):1420-31. doi: 10.1021/pr501084s. Epub 2015 Feb 23.

PMID:
25643065
25.

Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors.

All AH, Gharibani P, Gupta S, Bazley FA, Pashai N, Chou BK, Shah S, Resar LM, Cheng L, Gearhart JD, Kerr CL.

PLoS One. 2015 Jan 30;10(1):e0116933. doi: 10.1371/journal.pone.0116933. eCollection 2015.

26.

Risk-adjusted clinical outcomes in patients enrolled in a bloodless program.

Frank SM, Wick EC, Dezern AE, Ness PM, Wasey JO, Pippa AC, Dackiw E, Resar LM.

Transfusion. 2014 Oct;54(10 Pt 2):2668-77. doi: 10.1111/trf.12752. Epub 2014 Jun 18.

27.

Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature.

Anele UA, Mack AK, Resar LMS, Burnett AL.

Int Urol Nephrol. 2014 Sep;46(9):1733-1736. doi: 10.1007/s11255-014-0737-7. Epub 2014 May 14. Review.

28.

The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Huso TH, Resar LM.

Expert Opin Ther Targets. 2014 May;18(5):541-53. doi: 10.1517/14728222.2014.900045. Epub 2014 Mar 31. Review.

29.

Hitting the bull's eye: targeting HMGA1 in cancer stem cells.

Yanagisawa BL, Resar LM.

Expert Rev Anticancer Ther. 2014 Jan;14(1):23-30. doi: 10.1586/14737140.2013.859988.

30.

More common than you think: common variable immune deficiency.

Aderinto A, Mouli V, Resar DF, Resar LM.

Case Rep Hematol. 2013;2013:153767. doi: 10.1155/2013/153767. Epub 2013 Dec 5.

31.

Patent foramen ovale in patients with sickle cell disease and stroke: case presentations and review of the literature.

Razdan S, Strouse JJ, Naik R, Lanzkron S, Urrutia V, Resar JR, Resar LM.

Case Rep Hematol. 2013;2013:516705. doi: 10.1155/2013/516705. Epub 2013 Jul 16.

32.

Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia.

Hillion J, Belton AM, Shah SN, Turkson J, Jing N, Tweardy DJ, di Cello F, Huso DL, Resar LM.

Leuk Lymphoma. 2014 May;55(5):1194-7. doi: 10.3109/10428194.2013.821202. Epub 2013 Aug 13. No abstract available.

33.

HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells.

Shah SN, Cope L, Poh W, Belton A, Roy S, Talbot CC Jr, Sukumar S, Huso DL, Resar LM.

PLoS One. 2013 May 2;8(5):e63419. doi: 10.1371/journal.pone.0063419. Print 2013.

34.

A novel method of data analysis for utilization of red blood cell transfusion.

Frank SM, Resar LM, Rothschild JA, Dackiw EA, Savage WJ, Ness PM.

Transfusion. 2013 Dec;53(12):3052-9. doi: 10.1111/trf.12227. Epub 2013 Apr 29.

PMID:
23621848
35.

HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia.

Roy S, Di Cello F, Kowalski J, Hristov AC, Tsai HL, Bhojwani D, Meyer JA, Carroll WL, Belton A, Resar LM.

Leuk Lymphoma. 2013 Nov;54(11):2565-7. doi: 10.3109/10428194.2013.782610. Epub 2013 Apr 30. No abstract available.

36.

HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks.

Shah SN, Kerr C, Cope L, Zambidis E, Liu C, Hillion J, Belton A, Huso DL, Resar LM.

PLoS One. 2012;7(11):e48533. doi: 10.1371/journal.pone.0048533. Epub 2012 Nov 15.

37.

The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.

Hillion J, Smail SS, Di Cello F, Belton A, Shah SN, Huso T, Schuldenfrei A, Nelson DM, Cope L, Campbell N, Karikari C, Aderinto A, Maitra A, Huso DL, Resar LM.

Pancreatology. 2012 Jul-Aug;12(4):372-9. doi: 10.1016/j.pan.2012.05.005. Epub 2012 May 29.

38.

High mobility group A1 and cancer: potential biomarker and therapeutic target.

Shah SN, Resar LM.

Histol Histopathol. 2012 May;27(5):567-79. doi: 10.14670/HH-27.567. Review.

PMID:
22419021
39.

HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells.

Belton A, Gabrovsky A, Bae YK, Reeves R, Iacobuzio-Donahue C, Huso DL, Resar LM.

PLoS One. 2012;7(1):e30034. doi: 10.1371/journal.pone.0030034. Epub 2012 Jan 20.

40.

HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis.

Schuldenfrei A, Belton A, Kowalski J, Talbot CC Jr, Di Cello F, Poh W, Tsai HL, Shah SN, Huso TH, Huso DL, Resar LM.

BMC Genomics. 2011 Nov 4;12:549. doi: 10.1186/1471-2164-12-549.

41.

Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.

Nelson DM, Joseph B, Hillion J, Segal J, Karp JE, Resar LM.

Leuk Lymphoma. 2011 Oct;52(10):1999-2006. doi: 10.3109/10428194.2011.591012. Epub 2011 Jul 5.

42.

AKNA: another AT-hook transcription factor "hooking-up" with inflammation.

Moliterno AR, Resar LM.

Cell Res. 2011 Nov;21(11):1528-30. doi: 10.1038/cr.2011.96. Epub 2011 Jun 14. No abstract available.

43.

"Let"-ing go with clonal expansion?

Resar LM, Brodsky RA.

Blood. 2011 Jun 2;117(22):5788-90. doi: 10.1182/blood-2011-04-346668.

PMID:
21636715
44.

Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Chou BK, Mali P, Huang X, Ye Z, Dowey SN, Resar LM, Zou C, Zhang YA, Tong J, Cheng L.

Cell Res. 2011 Mar;21(3):518-29. doi: 10.1038/cr.2011.12. Epub 2011 Jan 18.

45.

Ghosal hematodiaphyseal dysplasia: a rare cause of a myelophthisic anemia.

Mazaheri P, Nadkarni G, Lowe E, Hines P, Vuica M, Griffin M, Resar LM.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1187-90. doi: 10.1002/pbc.22662.

PMID:
20672367
46.

The high mobility group A1 gene: transforming inflammatory signals into cancer?

Resar LM.

Cancer Res. 2010 Jan 15;70(2):436-9. doi: 10.1158/0008-5472.CAN-09-1212. Epub 2010 Jan 12. Review.

47.

Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.

Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, Di Cello F, Kowalski J, Elbahloul O, Segal J, Poirier J, Rudin CM, Dhara S, Belton A, Joseph B, Zucker S, Resar LM.

Mol Cancer Res. 2009 Nov;7(11):1803-12. doi: 10.1158/1541-7786.MCR-08-0336. Epub 2009 Nov 10.

48.

HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma.

Hristov AC, Cope L, Di Cello F, Reyes MD, Singh M, Hillion JA, Belton A, Joseph B, Schuldenfrei A, Iacobuzio-Donahue CA, Maitra A, Resar LM.

Mod Pathol. 2010 Jan;23(1):98-104. doi: 10.1038/modpathol.2009.139. Epub 2009 Oct 9.

49.

Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease.

Gabrovsky A, Aderinto A, Spevak M, Vichinsky E, Resar LM.

Pediatr Blood Cancer. 2010 Jan;54(1):148-50. doi: 10.1002/pbc.22295. Erratum in: Pediatr Blood Cancer. 2011 Mar;56(3):510. Aderinto, Abimbole [corrected to Aderinto, Abimbola].

PMID:
19785026
50.

The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?

Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, Turkson J, Jaganathan S, Cheng L, Ye Z, Jove R, Aplan P, Lin YW, Wertzler K, Reeves R, Elbahlouh O, Kowalski J, Bhattacharya R, Resar LM.

Cancer Res. 2008 Dec 15;68(24):10121-7. doi: 10.1158/0008-5472.CAN-08-2121.

Supplemental Content

Loading ...
Support Center